Summary

The global market for Glaucoma Treatment was estimated to be worth US$ 6478 million in 2024 and is forecast to a readjusted size of US$ 8705 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.
Glaucoma is one of the largest segments in the global ophthalmic market. Glaucoma can be treated with eye drops, pills, laser surgery, traditional surgery or a combination of these methods. The goal of any treatment is to prevent loss of vision, as vision loss from glaucoma is irreversible. The good news is that glaucoma can be managed if detected early, and that with medical and/or surgical treatment, most people with glaucoma will not lose their sight.
The accumulated burden of aging populations and chronic ophthalmic conditions is driving persistent demand for accessible IOP lowering and neuroprotective therapies. Clinical advances and commercialization roadmaps in sustained-release pharmacotherapies, minimally invasive surgical options and non-pharmacologic devices (such as wearable IOP management systems and pressure-adjusting pumps) have been explicitly incorporated into the medium- and long-term strategies of major listed players, expanding product categories and enabling geographic penetration. Robust reimbursement and regulatory frameworks in developed markets create premium opportunities for high-quality innovations, while improvements in primary eye care in emerging markets offer expansion levers. Companies that can translate R&D into compliant, scalable products and build differentiated channel and service models stand to amplify commercial value.

Key challenges include onerous regulatory and clinical evidence requirements, the need to demonstrate durable long-term safety and efficacy, and the difficulty of translating trial results into real-world adherence and outcomes. Novel devices and delivery systems often require prolonged clinical programs and intensive regulatory dialogue, which slows commercialization and raises costs; supply chain robustness, material sourcing and advanced manufacturing capability are critical risks for scale-up. Regulators place particular emphasis on patient experience and long-term surveillance in older populations; post-market issues can lead to high-visibility compliance and reputational risks.
End-user demand is shifting from pure efficacy toward a complete treatment experience: patients and providers prioritize dosing convenience, lowered long-term burden, comorbidity management and total cost of care. Hospitals and specialty clinics are receptive to reusable surgical adjuncts, complementary procedural products and service-linked solutions integrated with clinical pathways; home care and remote monitoring trends push manufacturers to design for usability and digital connectivity. Traditional distribution and institutional procurement remain significant, but direct-to-patient digital channels and retail are growing, elevating the importance of brand and end-user education.

This report aims to provide a comprehensive presentation of the global market for Glaucoma Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Glaucoma Treatment by region & country, by Product, and by Application.
The Glaucoma Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glaucoma Treatment.

Market Segmentation
By Company
Novartis
AbbVie
Pfizer
Akorn
Teva
Bausch & Lomb
Otsuka Pharmaceutical
Santen
Lunan Pharma
Zizhu Pharma
Segment by Product
Prostaglandin Analogs (PGAs)
Beta Blocker
Alpha Agonist
Others
Segment by Application
Clinic
Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glaucoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Product, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Glaucoma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Glaucoma Treatment in country level. It provides sigmate data by Product, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Glaucoma Treatment Product Introduction
1.2 Global Glaucoma Treatment Market Size Forecast (2020-2031)
1.3 Glaucoma Treatment Market Trends & Drivers
1.3.1 Glaucoma Treatment Industry Trends
1.3.2 Glaucoma Treatment Market Drivers & Opportunity
1.3.3 Glaucoma Treatment Market Challenges
1.3.4 Glaucoma Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Glaucoma Treatment Players Revenue Ranking (2024)
2.2 Global Glaucoma Treatment Revenue by Company (2020-2025)
2.3 Key Companies Glaucoma Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Glaucoma Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Glaucoma Treatment
2.6 Glaucoma Treatment Market Competitive Analysis
2.6.1 Glaucoma Treatment Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Glaucoma Treatment Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glaucoma Treatment as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Product
3.1 Introduction by Product
3.1.1 Prostaglandin Analogs (PGAs)
3.1.2 Beta Blocker
3.1.3 Alpha Agonist
3.1.4 Others
3.2 Global Glaucoma Treatment Sales Value by Product
3.2.1 Global Glaucoma Treatment Sales Value by Product (2020 VS 2024 VS 2031)
3.2.2 Global Glaucoma Treatment Sales Value, by Product (2020-2031)
3.2.3 Global Glaucoma Treatment Sales Value, by Product (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinic
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Glaucoma Treatment Sales Value by Application
4.2.1 Global Glaucoma Treatment Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Glaucoma Treatment Sales Value, by Application (2020-2031)
4.2.3 Global Glaucoma Treatment Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Glaucoma Treatment Sales Value by Region
5.1.1 Global Glaucoma Treatment Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Glaucoma Treatment Sales Value by Region (2020-2025)
5.1.3 Global Glaucoma Treatment Sales Value by Region (2026-2031)
5.1.4 Global Glaucoma Treatment Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Glaucoma Treatment Sales Value, 2020-2031
5.2.2 North America Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Glaucoma Treatment Sales Value, 2020-2031
5.3.2 Europe Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Glaucoma Treatment Sales Value, 2020-2031
5.4.2 Asia Pacific Glaucoma Treatment Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Glaucoma Treatment Sales Value, 2020-2031
5.5.2 South America Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Glaucoma Treatment Sales Value, 2020-2031
5.6.2 Middle East & Africa Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Glaucoma Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Glaucoma Treatment Sales Value, 2020-2031
6.3 United States
6.3.1 United States Glaucoma Treatment Sales Value, 2020-2031
6.3.2 United States Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.3.3 United States Glaucoma Treatment Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Glaucoma Treatment Sales Value, 2020-2031
6.4.2 Europe Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.4.3 Europe Glaucoma Treatment Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Glaucoma Treatment Sales Value, 2020-2031
6.5.2 China Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.5.3 China Glaucoma Treatment Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Glaucoma Treatment Sales Value, 2020-2031
6.6.2 Japan Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.6.3 Japan Glaucoma Treatment Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Glaucoma Treatment Sales Value, 2020-2031
6.7.2 South Korea Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.7.3 South Korea Glaucoma Treatment Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Glaucoma Treatment Sales Value, 2020-2031
6.8.2 Southeast Asia Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.8.3 Southeast Asia Glaucoma Treatment Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Glaucoma Treatment Sales Value, 2020-2031
6.9.2 India Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
6.9.3 India Glaucoma Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Profile
7.1.2 Novartis Main Business
7.1.3 Novartis Glaucoma Treatment Products, Services and Solutions
7.1.4 Novartis Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.1.5 Novartis Recent Developments
7.2 AbbVie
7.2.1 AbbVie Profile
7.2.2 AbbVie Main Business
7.2.3 AbbVie Glaucoma Treatment Products, Services and Solutions
7.2.4 AbbVie Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.2.5 AbbVie Recent Developments
7.3 Pfizer
7.3.1 Pfizer Profile
7.3.2 Pfizer Main Business
7.3.3 Pfizer Glaucoma Treatment Products, Services and Solutions
7.3.4 Pfizer Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.3.5 Pfizer Recent Developments
7.4 Akorn
7.4.1 Akorn Profile
7.4.2 Akorn Main Business
7.4.3 Akorn Glaucoma Treatment Products, Services and Solutions
7.4.4 Akorn Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.4.5 Akorn Recent Developments
7.5 Teva
7.5.1 Teva Profile
7.5.2 Teva Main Business
7.5.3 Teva Glaucoma Treatment Products, Services and Solutions
7.5.4 Teva Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.5.5 Teva Recent Developments
7.6 Bausch & Lomb
7.6.1 Bausch & Lomb Profile
7.6.2 Bausch & Lomb Main Business
7.6.3 Bausch & Lomb Glaucoma Treatment Products, Services and Solutions
7.6.4 Bausch & Lomb Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.6.5 Bausch & Lomb Recent Developments
7.7 Otsuka Pharmaceutical
7.7.1 Otsuka Pharmaceutical Profile
7.7.2 Otsuka Pharmaceutical Main Business
7.7.3 Otsuka Pharmaceutical Glaucoma Treatment Products, Services and Solutions
7.7.4 Otsuka Pharmaceutical Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.7.5 Otsuka Pharmaceutical Recent Developments
7.8 Santen
7.8.1 Santen Profile
7.8.2 Santen Main Business
7.8.3 Santen Glaucoma Treatment Products, Services and Solutions
7.8.4 Santen Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.8.5 Santen Recent Developments
7.9 Lunan Pharma
7.9.1 Lunan Pharma Profile
7.9.2 Lunan Pharma Main Business
7.9.3 Lunan Pharma Glaucoma Treatment Products, Services and Solutions
7.9.4 Lunan Pharma Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.9.5 Lunan Pharma Recent Developments
7.10 Zizhu Pharma
7.10.1 Zizhu Pharma Profile
7.10.2 Zizhu Pharma Main Business
7.10.3 Zizhu Pharma Glaucoma Treatment Products, Services and Solutions
7.10.4 Zizhu Pharma Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
7.10.5 Zizhu Pharma Recent Developments
8 Industry Chain Analysis
8.1 Glaucoma Treatment Industrial Chain
8.2 Glaucoma Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Glaucoma Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Glaucoma Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer